Journal of Mid-life Health Journal of Mid-life Health
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission | Subscribe | Advertise Users Online: 3146  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 


ORIGINAL ARTICLE
Year : 2022  |  Volume : 13  |  Issue : 1  |  Page : 80-84

Improvement in quality of life of postmenopausal women with depression with commonly used antidepressants (Escitalopram vs. Desvenlafaxine): A randomized controlled trial in a tertiary care teaching hospital of North India


1 Department of Pharmacology, Government Medical College, Jammu, Jammu and Kashmir; Department of Pharmacology, Government Medical College Medical College and Hospital, Sec-32, Chandigarh, India
2 Department of Psychiatry, Psychiatry Diseases Hospital, Jammu, Jammu and Kashmir, India
3 Department of Pharmacology, Government Medical College, Jammu, Jammu and Kashmir, India
4 Department of Internal Medicine, Government Medical College, Jammu, Jammu and Kashmir, India

Correspondence Address:
Sonia Shinde Mahajan
Department of Pharmacology, Govt. Medical College and Hospital, Sec 32, Chandigarh - 160 047
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmh.jmh_150_21

Rights and Permissions

Introduction: The postmenopausal symptoms affect the quality of life (QoL) of women. Depression and anxiety too have been associated with diminished QoL. It is known that antidepressants escitalopram and desvenlafaxine are effective in the treatment of depression and anxiety. However, to the best of our knowledge, their comparative effect on the QoL of postmenopausal women with depression and anxiety has not been studied in the Indian setup. Materials and Methods: The present study was a randomized, intention to treat, open-label trial undertaken in North India's a tertiary care teaching hospital. Postmenopausal women attending the psychiatry outpatient department and newly diagnosed with depression and anxiety were randomized in two groups to receive Tab. Escitalopram 10–20 mg and Tab. Desvenlafaxine 50–100 mg. Their QoL was assessed using the WHOQOL BREF scale at baseline, 3 weeks and 6 weeks. Results: Escitalopram was observed to be statistically better than desvenlafaxine in improving the overall QoL score of the WHOQOL-BREF scale. Individually, escitalopram significantly improved the scores of the physical health domain, psychological and environmental domains except for the social relationship domain. Desvenlafaxine significantly improved scores of all four domains. Conclusion: Escitalopram was observed to be significantly better than desvenlafaxine in improving the overall QoL scores. Both the drugs were well tolerated.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed128    
    Printed0    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal